Tumor associated macrophages polarization dictates the efficacy of BCG instillation in non-muscle invasive urothelial bladder cancer

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Suriano, Francesca ^a   Santini, Daniele ^b   Perrone, Giuseppe ^b   Amato, Michela ^b   Vincenzi, Bruno ^b   Tonini, Giuseppe ^b   Muda, Andrea Onetti ^b   Boggia, Sara ^c   Buscarini, Maurizio ^a   Pantano, Francesco ^b  

^a UNIVERSITY OF ROME G MARCONI   (Italy)

^b UNIVERSITY OF ROME   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bladder cancer; Endovescical instillation; Macrophages polarization; Prognosis; Tumor associated macrophages

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE; MALE; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; TRANSURETHRAL RESECTION; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84887088464     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-87     Document Type: Article

References (31)

1. Estimates of cancer incidence and mortality in Europe in 2008. Ferlay J, Parkin DM, Steliarova-Foucher E, Eur J Cancer 2010 46 765 781 10.1016/j.ejca.2009.12.014 20116997
2. Fleming JD, Cooper JS, Jenson DE, et al. AJCC cancer staging manual 5 1997
3. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables:a combined analysis of 2596 patients from seven EORTC trials. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Eur Urol 2006 49 3 465 466
4. An overview of the treatment of superficial bladder cancer. Duque JLF, Loughlin KR, Urol Clin North AM 2000 1 125 135 (Pubitemid 30086004)
5. Immunomodulatory effects of recombinant BCG ex pressing pertossi toxin on TNF-alfa and IL-10 in a bladder cancer model. Chade DC, Borra RC, Nascimento IP, Andrade PM, et al. J Exp Clin Cancer Res 2008 27 78 10.1186/1756-9966-27-78 19040745
6. Intracavitary bacillus calmette guerin in the treatment of superficial bladder tumors. Morales A, Eidinger D, Bruce AW, J Urol 1976 2 180 183
7. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus calmette guerin immunotherapy. Ayary C, LaRue H, Hovington H, Decobert M, Fradet Y, et al. Eur Urol 2009 55 6 1386 1396 10.1016/j.eururo.2009.01.040 19193487
8. The role of tumor associated macrophages in tumor progression: implications for new anticarncer terapie. Bingle L, Brown NJ, Lewis CE, J Pathol 2002 196 3 254 265 10.1002/path.1027 11857487 (Pubitemid 34189413)
9. FcRy activation regulates inflammation-associated squamous carcinogenesis. Andreu P, et al. Cancer Cell 2010 17 121 134 10.1016/j.ccr.2009.12.019 20138013
10. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. De Visser KE, Korets LV, Coussens LM, Cancer Cell 2005 7 411 423 10.1016/j.ccr.2005.04.014 15894262 (Pubitemid 40719125)
11. Macrophages and cancer. Nardin A, Abastado JP, Front Biosci 2008 13 3494 3505 18508451 (Pubitemid 351594699)
12. Histamine deficiency promotes inflammation-associated carcinogenesis through reduced myeloid maturation and accumulation of CD11b + Ly6G + immature myeloid cells. Yang XD, et al. Nature Med 2011 17 87 95 10.1038/nm.2278 21170045
13. Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. Sierra JR, et al. J Exp Med 2008 205 1673 1685 10.1084/jem.20072602 18559453 (Pubitemid 351962030)
14. Prognostic value of tumor-associated macrophage count in human bladder cancer. Hanada T, Nakagawa M, Emoto A, et al. Int J Urol 2000 7 263 269 10.1046/j.1442-2042.2000.00190.x 10910229 (Pubitemid 30440592)
15. Pharmacokinetics of combined gene therapy expressing constitutive human GM-CSF and hyperthermia-regulated human IL-12. Wei F, Wang H, Huang Q, et al. J Exp Clin Cancer Res 2013 32 5 10.1186/1756-9966-32-5 23352035
16. Pro-inflammatory type-1 and anti-inflammatory type-2 macrophages differentially modulate cell survival and invasion of human bladder carcinoma. Dufresne M, Dumas G, Asselin E, et al. Mol Immunol 2008 48 1556 1567
17. Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. Song L, Asgharzadeh S, Salo J, et al. J Clin Invest 2009 119 6 1524 1536 10.1172/JCI37869 19411762
18. Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. Jensen TO, Schmidt H, Moller HJ, et al. J Clin Oncol 2009 27 20 3330 3337 10.1200/JCO.2008.19.9919 19528371
19. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. Kurahara H, Shinchi H, Mataki Y, et al. J Surg Res 2011 167 2 211 e219 10.1016/j.jss.2009.05.026 19765725
20. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small cell lung cancer. Welsh TJ, Green RH, Richardson D, et al. J Clin Oncol 2005 23 35 8959 8967 10.1200/JCO.2005.01.4910 16219934 (Pubitemid 46211481)
21. Increased IL-10 mRNA expression in tumor associated macrophage correlated with late stage of lung cancer. Wang R, Lu M, Zhang J, Chen H, et al. J Exp Clin Cancer Res 2011 30 62 10.1186/1756-9966-30-62 21595995
22. High expression of nitric oxide synthases is a favorable prognostic sign in non-small cell lung carcinoma. Puhakka A, Kinnula V, Napankangas U, et al. APMIS 2003 111 12 1137 1146 10.1111/j.1600-0463.2003.apm1111210.x 14678024 (Pubitemid 38091254)
23. Prognostic significante of tumor necrosis factors and their receptors in nonsmall cell lung carcinoma. Tran TA, Kallakury BV, Ambros RA, et al. Cancer 1998 83 2 276 282 10.1002/(SICI)1097-0142(19980715)83:2<276::AID-CNCR11>3. 0.CO;2-Q 9669810 (Pubitemid 28317807)
24. iNOS expression in human intestinal microvascular endothelial cells inhibits leukocyte adhesion. Binion DG, Fu S, Ramanujam KS, et al. Am J Physiol 1998 275 3 Pt 1 592 G603 9724273
25. Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions: colocalization with epitome characteristics of oxidized LDL and peroxynitrite-modified proteins. Luoma JS, Stralin P, Marklund SL, et al. Arterioscler Thromb Vasc Biol 1998 18 2 157 167 10.1161/01.ATV.18.2.157 9484979 (Pubitemid 28277591)
26. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. Cunningham D, Allum WH, Stenning SP, et al. N Engl J Med 2006 355 1 11 20 10.1056/NEJMoa055531 16822992
27. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomized controlled surgical trial. Cuschieri A, Fayers P, Fielding J, The Surgical Cooperative Group, et al. Lancet 1996 347 9007 995 999 10.1016/S0140-6736(96)90144-0 8606613 (Pubitemid 26112171)
28. Role of tumor-associated macrophages (TAM) in advanced gastric carcinoma: the Impact on FasL-mediated counterattack. Ohno S, Inagawa H, Dhar DK, et al. Anticancer Res 2005 25 1B 463 470 15816613 (Pubitemid 40470051)
29. CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Moestrup SK, Moller HJ, Ann Med 2004 36 347 354 10.1080/07853890410033171 15478309 (Pubitemid 39233102)
30. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. Stout RD, Jiang C, Matta B, et al. J Immunol 2005 175 342 349 15972667 (Pubitemid 40884337)
31. Expression of HLA-DR is reduced in tumor infiltrating immune cells (TIICs) and regional lymph nodes of non-small cell lung carcinomas: a putative mechanism of tumor-induced immunosuppression? Foukas PG, Tsilivakos V, Zacharatos P, et al. Anticancer Res 2001 21 4A 2609 2615 11724329 (Pubitemid 33054432)